A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC

Trial Profile

A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2015

At a glance

  • Drugs Icotinib (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Beta Pharma
  • Most Recent Events

    • 05 Sep 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 05 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 29 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top